Physical Therapists in Belle Mead, NJ Accepting Medicare
7 Physical Therapists found. Showing 1 - 7
 Life Health Physical Therapy Llc Physical Therapist Medicare: Medicare Enrolled Practice Location: 245 Township Line Rd, Belle Mead, NJ 08502 Phone: 908-625-4558 |
 Patricia Maciborski, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 71 Grist Mill Dr, Belle Mead, NJ 08502 Phone: 908-874-4883 |
Jessica Nevis, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 21 Bellemead Griggstown Rd # 102-103, Belle Mead, NJ 08502 Phone: 908-533-7733 |
Barbara Kelly, PT Physical Therapist - Geriatrics Medicare: Medicare Enrolled Practice Location: 245 Township Line Rd, Belle Mead, NJ 08502 Phone: 908-625-4558 Fax: 908-359-2514 |
Dr. Teresa Elizabeth Lynch Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 12 Westminster Ct, Belle Mead, NJ 08502 Phone: 908-904-4657 Fax: 908-904-4658 |
Sumeet Girotra Physical Therapist Medicare: Medicare Enrolled Practice Location: 106 Woodview Dr, Belle Mead, NJ 08502 Phone: 609-712-0918 |
Mrs. Priya Krishnan, BPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 7 Hudnut Ln, Belle Mead, NJ 08502 Phone: 908-655-1282 |
News Archive
Beta-blockers improve overall survival among epithelial ovarian cancer patients
In a first-of-its-kind study, researchers demonstrate a benefit in overall survival among epithelial ovarian cancer (EOC) patients receiving generic heart medications known as beta-blockers. Survival was shown to be greatest among those prescribed first-generation nonselective beta-blockers.
Vedantra and Neon Therapeutics extend research alliance to develop impactful cancer therapies
Vedantra Pharmaceuticals, Inc., an immunotherapy company focused on developing products to treat cancer and infectious disease, and Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T-cell therapies to treat cancer, announced today that the companies have extended their non-exclusive research alliance.
New version of Belmont Rapid Infuser to be introduced at ASA 2014
Belmont Instrument Corporation, the widely recognized provider of blood and fluid infusers, will be introducing the new version of The Belmont Rapid Infuser, the RI-2 at the American Society of Anesthesiologists Meeting this week in New Orleans, LA.
FDA approves Ascenta's IND for AT-406 multi-IAP antagonist
Ascenta Therapeutics announced today that following the approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) Application for AT-406, an orally-active, small molecule, multi-IAP antagonist, the company will initiate a Phase I clinical trial in patients with advanced cancer during the fourth quarter of 2009.
Conference to explore new discoveries about origins, diagnosis and treatment of tinnitus
University at Buffalo research showing that a new drug that eliminated tinnitus with a single dose in animal models is among the advances that will be presented at the Fifth Tinnitus Research Initiative Conference, "The Neuroscience of Tinnitus," sponsored by UB's Center for Hearing and Deafness Aug. 19-21 in Grand Island, N.Y.
› Verified 8 days ago
Physical Therapists
Occupational Therapists
Speech-Language Pathologists